| Detected | Trial | Change |
|---|---|---|
| 2026-08-15 | NCT06627647 A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for… · AstraZeneca |
Trial sites expanded: 287 -> 295 locations |
| 2026-08-15 | NCT05758116 Tislelizumab Consolidation Therapy After Radiotherapy or Sequential Chemoradiation in… · Peking University Cancer Hospital & Institute |
Trial completed |
| 2026-08-15 | NCT05758116 Tislelizumab Consolidation Therapy After Radiotherapy or Sequential Chemoradiation in… · Peking University Cancer Hospital & Institute |
Enrollment reduced: 20 -> 5 participants |
| 2026-08-15 | NCT05758116 Tislelizumab Consolidation Therapy After Radiotherapy or Sequential Chemoradiation in… · Peking University Cancer Hospital & Institute |
date change Primary completion pushed: 2025-07-07 -> 2026-06-30 |
| 2026-08-15 | NCT06822543 A Single Arm, Phase 2 Study of Datopotamab Deruxtecan, Carboplatin, and Pembrolizumab for… · Latin American Cooperative Oncology Group |
Trial sites expanded: 1 -> 13 locations |
| 2026-08-15 | NCT06694454 Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab… · National Cancer Institute (NCI) |
critical Recruitment suspended |
| 2026-08-15 | NCT06694454 Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab… · National Cancer Institute (NCI) |
critical Recruitment suspended: Placed on voluntary hold to new recruitment pending modification to combination monoclonal antibody treatment. |
| 2026-08-14 | NCT05572684 A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants… · NextCure, Inc. |
critical Trial terminated |
| 2026-08-14 | NCT05572684 A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants… · NextCure, Inc. |
critical Trial terminated: Following completion of Phase 1b, the Sponsor decided not to initiate Part 2 of the trial. |
| 2026-08-14 | NCT05572684 A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants… · NextCure, Inc. |
Primary endpoint(s) modified |
| 2026-08-14 | NCT05572684 A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants… · NextCure, Inc. |
date change Primary completion moved earlier: 2025-07 -> 2025-04-30 |
| 2026-08-14 | NCT05572684 A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants… · NextCure, Inc. |
date change Completion moved earlier: 2025-11 -> 2025-04-30 |
| 2026-08-14 | NCT04853342 To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With… · Allist Pharmaceuticals, Inc. |
date change Primary completion pushed: 2026-01 -> 2026-12 |
| 2026-08-14 | NCT03782207 A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions… · Hoffmann-La Roche |
Trial completed |
| 2026-08-14 | NCT05288205 Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors… · Allist Pharmaceuticals, Inc. |
date change Primary completion pushed: 2026-03 -> 2027-03 |
| 2026-08-14 | NCT05288205 Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors… · Allist Pharmaceuticals, Inc. |
date change Completion pushed: 2026-03 -> 2027-03 |
| 2026-08-14 | NCT07111936 Evaluating the Impact of CONNECT in a Multilingual Population · University of California, San Francisco |
Recruitment opened |
| 2026-08-14 | NCT07593248 Real-World Outcomes of Resected EGFR-Mutated NSCLC Patients Treated With Adjuvant… · AstraZeneca |
Trial sites expanded: 1 -> 14 locations |
| 2026-08-14 | NCT05920356 A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum… · Amgen |
Trial sites expanded: 407 -> 412 locations |
| 2026-08-14 | NCT06416410 JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced… · Allist Pharmaceuticals, Inc. |
date change Primary completion pushed: 2026-09-30 -> 2029-09-30 |
| First Posted | Trial | Sponsor | Phase |
|---|---|---|---|
| 2026-08-14 | NCT07766538 Feasibility and Uptake of Low-Dose CT Lung Cancer Screening in Kuwait | Sulaiman Khadadah NEW | |
| 2026-08-10 | NCT07754409 Aspects of Quality of Life During Adjuvant Oncological Treatment for Locally Advanced… | Göteborg University NEW | |
| 2026-08-10 | NCT07755501 Virtual Reality in Lung Cancer Patients | Dott.Claudio Sini NEW | |
| 2026-08-10 | NCT07755397 First in Human Multicenter Open Name Dose-increase, Consolidation Method to Study Safety… | Jubilant Therapeutics India Limited NEW | Phase 1 |
| 2026-08-10 | NCT07755020 Nitride-Based Raman Biochip for Lung Cancer Diagnosis and Monitoring | Taichung Veterans General Hospital NEW | |
| 2026-08-07 | NCT07751536 ctDNA-driven Adaptive Proton Craniospinal Irradiation in Non-Small Cell Lung Cancer With… | Shuanghu Yuan NEW | |
| 2026-08-06 | NCT07749950 Effects of Early Mobilization and Feeding After Lobectomy | Ege University NEW | |
| 2026-08-05 | NCT07746323 Effect of Modified Arm Positioning on Shoulder Pain After Thoracoscopic Lobectomy | Chengdu Jinjiang Maternity and Child Health Hospital NEW | |
| 2026-08-04 | NCT07743775 CT-Free Electromagnetic Navigation Percutaneous Localization for Pulmonary Nodules… | Jianle Chen NEW | |
| 2026-08-04 | NCT07744529 Amivantamab Combined With Intrathecal Pemetrexed for LM From EGFR-Mutated Lung… | Second Affiliated Hospital, Zhejiang University, School of Medicine NEW | Phase 1/2 |
| NCT ID | Title | Sponsor | Status |
|---|---|---|---|
| Phase 4 | |||
| NCT05172739 | Opioid Free Anaesthesia-Analgesia Strategy on Surgical Stress and Immunomodulation in… | University of Crete | Recruiting |
| NCT05663242 | The Effects of Using Different Anesthetics on the Prognosis of Primary Lung Tumors and… | Kaohsiung Medical University Chung-Ho Memorial Hospital | Recruiting |
| NCT05525338 | Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib… | University Medical Center Groningen | Recruiting |
| NCT06467786 | Study on the Therapeutic Effect of Irinotecan Liposomes in Small Cell Lung Cancer | Tang-Du Hospital | Recruiting |
| NCT05748093 | Improving Osimertinib Exposure and Cost-effectiveness Using Pharmacokinetic Boosting With… | Maastricht University Medical Center | Recruiting |
| NCT05463913 | Lung Nodule Detection Using Ultra-long FOV PET/CT | University Medical Center Groningen | Recruiting |
| NCT06908070 | Chemoradiotherapy With Surgery Followed by Consolidation Durvalumab | Idris Bahce | Recruiting |
| NCT05874401 | Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)… | Pharmacosmos A/S | Recruiting |
| NCT07320105 | Postoperative Radiotherapy for Postoperative N2 Metastases of NSCLC in the Immunotherapy… | Fujian Cancer Hospital | Recruiting |
| NCT06105801 | EBUS-TBNA vs Transbronchial Mediastinal Cryobiopsy for Adequacy of Next Generation… | Vanderbilt-Ingram Cancer Center | Recruiting |
| NCT06330038 | Anesthesia and Non-small Cell Lung Cancer Recurrence | Samsung Medical Center | Recruiting |
| NCT06646471 | PROspective Master-protocol for Evaluation of Systemic THErapeutics in Elderly With… | GFPC Investigation | Recruiting |
| NCT07279935 | Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After… | AstraZeneca | Recruiting |
| NCT07405086 | Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or… | OHSU Knight Cancer Institute | Recruiting |
| NCT03340506 | Dabrafenib and/or Trametinib Rollover Study | Novartis Pharmaceuticals | Recruiting |
| NCT07744698 | Metronomic Oral Paclitaxel Plus PD-1/ PD-L1 Inhibitor Maintenance in Advanced Lung Cancer… | Anhui Provincial Cancer Hospital | Recruiting |
| NCT07704658 | Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors | Rigel Pharmaceuticals | Recruiting |
| NCT07754812 | Oral Paclitaxel Solution With Immunotherapy and Concurrent SBRT as Neoadjuvant Treatment… | Shanghai Pulmonary Hospital, Shanghai, China | Recruiting |
| NCT06276933 | A Study of Camrelizumab Combined With Chemotherapy ± Thalidomide in First-line Treatment… | Tongji University | Not Yet Recruiting |
| NCT06483009 | Efficacy and Safety of Combination Therapy of Sintilimab and Chemotherapy With… | Shanghai Chest Hospital | Not Yet Recruiting |
| NCT06785584 | Efficacy and Safety of Ensartinib in Neoadjuvant Therapy for Stage IIA - IIIB (Operable… | Fujian Medical University Union Hospital | Not Yet Recruiting |
| NCT06931145 | Benmelstobart, Anlotinib and Chemotherapy as First-line Treatment for Extensive-stage… | Peking Union Medical College Hospital | Not Yet Recruiting |
| NCT06951841 | Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome… | China Medical University, China | Not Yet Recruiting |
| NCT05144997 | Lorlatinib Continuation Study | Pfizer | Active, Not Recruiting |
| NCT05689671 | Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung… | Nikolaj Frost MD | Active, Not Recruiting |